Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
WITHDRAWN
NCT01203371
PHASE3

Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS

Sponsor: Apsen Farmaceutica S.A.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.

Official title: PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF NAFTOPIDIL AND TAMSULOSIN TO TREATMENT THE SYMPTOMS OF LOWER URINARY TRACT IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA

Key Details

Gender

MALE

Age Range

50 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

0

Start Date

2011-01-01

Completion Date

2012-01-01

Last Updated

2026-09-09

Healthy Volunteers

No

Conditions

Interventions

DRUG

Naftopidil

0,25 mg (2weeks) and 0,50 mg (10 weeks)

DRUG

Tamsulosin

0,4 mg/day

Locations (1)

Hospital das Clínicas da Faculdade de Medicina da USP

São Paulo, São Paulo, Brazil